Xconomy: Houstons Bellicum Pharma Rides T-Cell Therapy Wave to $140M IPO
Summary
Houston’s Bellicum Pharma Rides T-Cell Therapy Wave to $140M IPO (Page 2 of 2) with a surface protein that helps them latch onto antibodies.And companies in the space are combating ways to fend off an overdrive of the immune system called cytokine release syndrome that these immunotherapies can provoke.“The product allows the physician to not have to worry about graft versus host (GVH) disease,” Bellicum CEO Tom Farrell told me in an interview this past August.“The cells can be eliminated in the event that GVH occurs.” Bellicum is developing that as an adjunct therapy administered after a bone marrow transplant.Bellicum additionally has a few other preclinical candidates in its pipeline that it’s developing as cellular immunotherapies for blood cancers, solid tumors, and melanoma.